Pascall Systems, Inc.

Pascall Systems, Inc., a for-profit manufacturer of medical devices based in Boston, Massachusetts, develops neuroscience-based anesthesia monitoring and brain-state assessment technologies for federal biomedical research funding as a prime recipient under National Institutes of Health grant programs. The company operates exclusively in the federal grant space — all nine recent awards are prime grants from NIH institutes, with no federal contract work or subcontracting activity.

Pascall's customer base is concentrated within NIH's three intramural institutes. The National Institute on Aging has awarded the company six grants totaling approximately $16.8 million to date, focused on commercialization-readiness development and clinical validation of wireless EEG-guided anesthesia management systems designed to prevent postoperative delirium in elderly patients and those at risk for Alzheimer's disease and related dementias. The National Institute of Neurological Disorders and Stroke has funded two grants, most recently a $199,806 award in July 2026 under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop event-related potential (ERP) technology for real-time nociception and pain assessment during regional anesthesia, general anesthesia, and postoperative care. The National Institute on Drug Abuse has placed one award in the source data. Combined obligated dollars across all nine awards total $42.4 million, with eight awards reaching ultimate completion within the next twenty-four months, presenting significant recompete exposure.

Pascall's capability portfolio centers on FDA-cleared wireless EEG monitoring hardware and personalized algorithms for intraoperative anesthesia decision support. The company achieved FDA 510(k) pre-market clearance of its M0 wireless anesthetic brain monitor in May 2022 and is now advancing toward M1, a next-generation integrated system with EMR, infusion pump, and anesthesia machine connectivity for clinical decision support in pain and anesthetic depth monitoring. Recent grant work includes a $5.995 million National Institute on Aging award in September 2025 (CFDA 93.866, Aging Research program) for commercialization readiness, Aim 1 pilot study design, and manufacturing scale-up under ISO 13485:2016 standards running through May 31, 2027; an August 2024 NIA award for development of age-compensated brain-state tracking, anesthetic dose guidance, and postoperative delirium risk prediction algorithms validated against datasets of 108,968 subjects; and a September 2023 NINDS grant for active stimulation and monitoring technologies targeting event-related potentials to assess pain during regional anesthesia, addressing a market gap where no FDA-cleared products currently exist for intraoperative nociception monitoring. Work is performed in Boston and Cambridge, Massachusetts.